Buy Tantum lozenges 3 mg 20 pcs
  • Buy Tantum lozenges 3 mg 20 pcs

Tantum® [Benzydamine]

1273 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$24.44
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Local anesthetic, anti-inflammatory local.

Indications

Symptomatic therapy of pain syndrome of inflammatory diseases of the oral cavity and ENT organs (of various etiologies):

  • gingivitis, glossitis, stomatitis (including after radiation and chemotherapy);
  • pharyngitis, laryngitis, tonsillitis;
  • candidiasis of the oral mucosa (in combination therapy);
  • calculous inflammation of the salivary glands;
  • condition after surgery and injuries (tonsillectomy, jaw fractures);
  • condition after treatment and removal of teeth;
  • periodontal disease.

In infectious and inflammatory diseases that require systemic treatment, Tantum® Verde should be used as part of a combination therapy.

Composition

Active ingredient: benzydamine hydrochloride 3 mg.
Excipients: isomaltose - 3183 mg; levomenthol - 4 mg; aspartame, 3.5 mg; citric acid monohydrate - 2 mg; Mint flavor - 5 mg; lemon flavor - 1.5 mg; quinoline yellow dye (E104) - 0.035 mg; indigo carmine dye (Е132) - 0,015 mg.

Benzydamine is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Tantum lozenges
Tantum Aziende Kimike Riunite Angelini Francesco A.K.R.A Italy lozenges
Tantum Rosa Aziende Kimike Riunite Angelini Francesco A.K.R.A Italy powder
Tantum Rosa Aziende Kimike Riunite Angelini Francesco A.K.R.A Italy solution
Tantum Aziende Kimike Riunite Angelini Francesco A.K.R.A Italy solution
Tantum Verde Aziende Kimike Riunite Angelini Francesco A.K.R.A Italy spray
Anhidak spray
Tantum Aziende Kimike Riunite Angelini Francesco A.K.R.A Italy spray

No customer reviews for the moment.

Write your review

Write your review

Tantum® [Benzydamine]

Dosage and Administration

Locally, after meals. To hold pills in a mouth before full dissolution, not to swallow, not to chew.
The duration of treatment should not exceed 7 days. If after treatment within 7 days of improvement does not occur or new symptoms appear, you should consult with your doctor.
Use the drug should only according to the method of application and in those doses that are listed in the description. If necessary, you should consult with your doctor before using the drug.
Adults (including elderly patients) and children over 6 years old: 1 tabl. for sucking 3 times a day. Do not exceed the recommended dose. In children from 6 to 12 years old, the use of the drug is made under the supervision of an adult.

Adverse reactions

Classification of the incidence of side effects WHO: very often - ≥1 / 10; often from ≥1 / 100 to <1/10; infrequently - from ≥1 / 1000 to <1/100; rarely from ≥1 / 10000 to <1/1000; very rarely - <1/10000; frequency unknown - cannot be estimated based on available data.
In each group, unwanted effects are presented in order of decreasing severity.
Local reactions: rarely - dry mouth, burning in the mouth; frequency unknown - feeling numb in the mouth.
Allergic reactions: infrequently - photosensitivity; rarely, hypersensitivity reactions, skin rash, pruritus; very rarely - angioedema, laryngospasm; frequency unknown - anaphylactic reaction.
If any of the side effects indicated in the description are aggravated or any other side effects that are not mentioned in the description are noted, you should immediately inform your doctor.

Contraindications

  • Hypersensitivity to benzydamine or other components of the drug;
  • fructose intolerance;
  • children's age up to 6 years.

With care: hypersensitivity to acetylsalicylic acid or other NSAIDs; bronchial asthma (including in history).

Special instructions

At use of the drug Tantum® Verde development of reactions of hypersensitivity is possible. In this case, it is recommended to discontinue treatment and consult a doctor for the appointment of appropriate therapy. In a limited number of patients, the presence of ulcers in the throat and oral cavity may indicate the presence of a more serious pathology. If the symptoms persist for more than 3 days, you should consult with your doctor.
The use of the drug Tantum® Verde is not recommended in patients with hypersensitivity to acetylsalicylic acid or other NSAIDs.
Tantum® Verde should be used with caution in patients with a history of bronchial asthma because they may develop bronchospasm while taking the drug.
The drug contains isomaltose, and therefore is not recommended for patients with hereditary fructose intolerance.
Use of the drug in children is possible only under the supervision of adults in order to avoid swallowing the pill.
Influence on ability to steer vehicles, mechanisms.
Does not affect.

Overdosage

Currently, cases of overdose of Tantum® Verde have not been reported.
Symptoms: when using the drug in accordance with the description of overdose is unlikely. If the drug is swallowed accidentally, vomiting, abdominal cramps, anxiety, fear, hallucinations, convulsions, ataxia, fever, tachycardia, respiratory depression are possible.
Treatment: symptomatic; induction of vomiting or gastric lavage using a gastric tube (under medical supervision); provide medical observation, maintenance therapy and necessary hydration. The antidote is unknown.

  • Brand name: Tantum
  • Active ingredient: Benzydamine
  • Dosage form: Lozenges.
  • Manufacturer: Aziende Kimike Riunite Angelini Francesco A.K.R.A.

Studies and clinical trials of Benzydamine (Click to expand)

  1. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis : Results from a multicenter, randomized, double-blind, placebo-controlled clinical trial
  2. Pharmacokinetics of benzydamine after intravenous, oral, and topical doses to human subjects
  3. Bioequivalence study of two liquid formulations of benzydamine
  4. Photodegradation of benzydamine: Phototoxicity of an isolated photoproduct on erythrocytes
  5. An Assay of Flavin-Containing Monooxygenase Activity with Benzydamine N-Oxidation
  6. Determination of the fluorescent drugs dipyridamole and benzydamine in rat plasma by liquid chromatography with peroxyoxalate chemiluminescence detection
  7. A study of the photodegradation of benzydamine in pharmaceutical formulations using HPLC with diode array detection
  8. High-performance liquid chromatographic determination of 1-benzyl-1H-indazol-3-ol in benzydamine in pharmaceutical formulations
  9. Photoproducts of benzydamine and azapropazone: Demonstration of their phototoxicity in vitro
  10. Spectrophotometric determination of benzydamine HCl, levamisole HCl and mebeverine HCl through ion-pair complex formation with methyl orange
  11. High-performance liquid chromatography assay for the measurement of benzydamine hydrochloride in topical pharmaceutical preparations
  12. Determination of benzydamine and its N-oxide in biological fluids by high-performance liquid chromatography
  13. Amperometric biosensor based on monoamine oxidase (MAO) immobilized in sol–gel film for benzydamine determination in pharmaceuticals
  14. Electron-transfer mechanisms in photosensitization by the anti-inflammatory drug benzydamine
  15. Benzydamine: an alternative nonsteroidal anti-inflammatory drug in patients with nimesulide-induced urticaria
  16. Photocontact dermatitis after gargling with a solution containing benzydamine
  17. Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity
  18. Pharmacokinetics of benzydamine in dairy cows following intravenous or intramuscular administration
  19. Effect of benzydamine on exocytosis and respiratory burst in human neutrophils and mononuclear phagocytes
  20. Effect of benzydamine, a topically administered NSAID onin vitroprostanoid synthesis by human and rat gastric mucosa and rat kidney, aorta and urinary bladder: Lack of effect on cyclooxygenase but potent inhibition of receptor-linked prostanoid synthesis
  21. Benzydamine inhibits the release of tumor necrosis factor-α and monocyte chemotactic protein-1 byCandida albicans-stimulated human peripheral blood cells
  22. Benzydamine protection in a mouse model of endotoxemia
  23. Differential effect of benzydamine on pro- versus anti-inflammatory cytokine production: lack of inhibition of interleukin-10 and interleukin-1 receptor antagonist

Customers who bought this product also bought:

8 other products in the same category:

arrow_upward